Financial Performance - The company's operating revenue for Q1 2024 was CNY 528,459,397.27, representing a 17.00% increase compared to the same period last year [2]. - The net profit attributable to shareholders for Q1 2024 was CNY 32,545,358.40, reflecting a 4.58% increase year-over-year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 30,743,149.96, up by 5.31% from the previous year [2]. - Total revenue for Q1 2024 reached ¥528,459,397.27, an increase of 17.0% compared to ¥451,680,716.64 in Q1 2023 [14]. - Operating profit for Q1 2024 was ¥46,683,061.07, up from ¥41,538,555.66 in Q1 2023, reflecting a growth of 10.3% [14]. - Net profit for Q1 2024 was ¥36,998,598.44, compared to ¥35,060,507.57 in Q1 2023, representing an increase of 5.5% [14]. - The company achieved a gross profit margin of approximately 48.5% in Q1 2024, compared to 47.5% in Q1 2023, indicating improved operational efficiency [17]. - Total comprehensive income for the period was CNY 36,917,239.32, compared to CNY 35,060,507.57 in the previous year, marking a growth of 5.3% [15]. Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -17,883,555.80, indicating a significant cash outflow [2]. - The net cash flow from operating activities was negative at CNY -17,883,555.80, slightly worse than the previous year's loss of CNY -16,026,393.23 [18]. - Cash and cash equivalents at the end of Q1 2024 were CNY 198,636,200.73, down from CNY 236,216,304.84 at the end of Q1 2023, a decrease of 15.9% [18]. - The company’s cash outflow from investing activities was CNY -34,576,429.51, an improvement from CNY -47,453,146.95 in Q1 2023 [18]. - The total assets at the end of Q1 2024 were CNY 2,829,972,908.92, a decrease of 0.90% from the end of the previous year [2]. - Total assets decreased to ¥2,829,972,908.92 as of March 31, 2024, from ¥2,855,702,313.77 at the end of 2023, a decline of 0.9% [12]. - Current assets totaled ¥1,302,483,966.20, down from ¥1,353,403,011.17, a decrease of 3.7% [10]. - The total liabilities decreased to ¥1,275,745,406.30 from ¥1,338,392,050.47, a reduction of 4.7% [11]. - Inventory decreased to ¥293,398,068.13 from ¥315,447,840.27, a decline of 7.0% [10]. - The company reported a decrease in accounts receivable to ¥515,768,173.15 from ¥488,615,601.43, an increase of 5.6% [10]. Shareholder Information - The equity attributable to shareholders at the end of Q1 2024 was CNY 1,386,653,076.78, which is a 2.40% increase compared to the end of the previous year [2]. - The total equity attributable to shareholders increased to ¥1,386,653,076.78 from ¥1,354,189,077.50, an increase of 2.4% [11]. - The basic and diluted earnings per share for Q1 2024 were both CNY 0.11, unchanged from the previous year [2]. - The company’s diluted earnings per share remained stable at CNY 0.11 for both Q1 2024 and Q1 2023 [15]. - The total number of ordinary shareholders at the end of the reporting period was 31,160 [5]. Government Support and Future Plans - The company received government subsidies amounting to CNY 2,607,561.70 during the reporting period [4]. - The company plans to continue focusing on market expansion and new product development to drive future growth [16]. Research and Development - Research and development expenses increased to ¥17,743,834.23 in Q1 2024, compared to ¥9,520,142.33 in Q1 2023, a rise of 86.5% [14].
联环药业(600513) - 2024 Q1 - 季度财报